Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(13)
•••
Post by gudisgoodon Jan 24, 2024 8:11am
145 Views
Post# 35842462

Promotions

PromotionsA few promotions / title changes within the Executives at Knight.

Monica Percario
Ms. Percario joined Knight as Global VP of Scientific Affairs in August 2021 and appointed to Global VP Regulatory and Quality in January 2024.
 
Henrique Diaz
Mr. Dias joined Knight as Global Director of Marketing in December 2021 and promoted to Global VP of Marketing in January 2024.
 
Melanie Groleau
Ms. Groleau joined Knight as Senior Director – Scientific Affairs for Canada in October 2019. In July 2021, Ms. Groleau was promoted to Global Senior Director PV &amp; Medical Information and Scientific Affairs Advisor for Canada. In May 2022, Ms. Groleau took on the role of Global Senior Director Medical Affairs. Ms. Groleau was promoted to VP Medical and Clinical in January 2024.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities